Gene transfer vectors expressing herpes simplex thymidine kinase (HSVtk), in addition to direct killing of tumor cells, often have an associated local 'bystander effect' mediated by metabolic coupling of tumor cells. A systemic antitumor effect mediated by the immune system, termed the distant bystander effect, has also been reported. We have observed the development of cytotoxic T-lymphocyte (CTL) popu-
Introduction
Malignant tumors of the nervous system are generally rapidly fatal despite recent advances in neurosurgical techniques, radiation therapy, and chemotherapy.
1,2 Antiglioma gene therapy with retroviral vector producer cells secreting a vector expressing the herpes simplex thymidine kinase (HSVtk) transgene has been reported. [3] [4] [5] [6] This treatment can generate a significant local antitumor effect mediated by tumoricidal metabolites generated by HSVtk activation of the prodrug ganciclovir (GCV). Clinically significant responses occurred in five of 19 tumors treated in 15 evaluable patients, with responses lasting between 4 and 220 weeks, in a human clinical trial. 7 Much of the therapeutic effect of the HSVtk/GCV system is believed to be due to a local 'bystander effect' that results in killing of adjacent non-transduced tumor cells. Addition of GCV to mixtures of cells containing as few as 10% HSVtk expressing tumor cells can result in 100% killing, presumably by movement of phosphorylated GCV, the activated form of the prodrug, through gap junctions. 8, 9 Despite the amplified tumor killing provided by the bystander effect, the limited distribution of vector within solid tumors makes cure mediated by the direct toxicity of GCV metabolites, even of local lesions.
Recently, several studies have suggested that vaccination therapy may eradicate or reduce existing tumor deposits to subclinical levels, as well as provide long- term protection from regrowth of tumor cells. [10] [11] [12] Manipulation of immune mechanisms as a strategy for the treatment of central nervous system (CNS) tumors has been proposed, 13 but few antigens of significant therapeutic and diagnostic utility have been described. 14 Several studies have suggested that an immune component may also contribute to the elimination of HSVtk modified tumor cells after GCV treatment. 15 HSVtkmediated killing of tumor cells may represent an effective means of obtaining tumor lysis and thus potentiate antigen presentation. 16 Ashley et al, 13 Yu et al, 17 and Nair et al 18 have demonstrated that vaccination strategies can stimulate protective immunity to tumor deposits in the CNS. Using 9L cell lines stably transduced and selected for HSVtk expression, the efficacy of subcutaneous tumor cell vaccines in the treatment of intracranial 9L tumors has been reported. 19 Immunity against an intracranial tumor following in situ subcutaneous tumor lysis as tumor vaccine has been also observed with HSV vectors. 20 However, a vaccination effect with intracranial protection after adenovirus mediated in vivo transduction of subcutaneous tumor with HSVtk has not yet been demonstrated.
The ability of adenovirus vaccines to induce strong immune responses in several non-tumor models suggests that they might be useful in developing vaccines for cancer therapy. 21 Furthermore, adenoviral vectors have several potential advantages over the use of retroviral vectors or vector producer cells for gene delivery to tumors. These include a smaller virion size which may permit greater intratumoral distribution, 22 growth to titers much higher than that achievable with retrovirus vectors, 23 and efficient transduction of non-dividing tumor cells. 24 Fur-thermore, adenoviruses are not affected by the complement-mediated elimination of xenogeneic vector producer cells and their retroviral product. 25 Gene expression in adenoviral vectors is transient, but of sufficient duration to permit successful treatment of gliomas in rat and mouse models. [26] [27] [28] [29] In this report, we examined whether in situ treatment of subcutaneous tumor deposits with an adenoviral vector expressing HSVtk (AV.TK) and ganciclovir (GCV) (AV.TK/GCV) could effect the growth of tumors in the CNS.
Results

HSVtk/GCV mediated blockade/elimination of subcutaneous 9L tumors
The efficacy of various therapies aimed at blocking or ablating 9L subcutaneous tumors is shown in Table 1 . In the case of cells which had received some degree of lethal injury in culture (irradiation or GCV treatment ex vivo), the effect of each treatment on the inoculated cells was estimated by the blockade of tumor growth. As for cells which received lethal injury in vivo, the effect was estimated by tumor elimination. Animals receiving 9L cells alone formed tumors which rapidly progressed, and when untreated, required killing in [35] [36] [37] [38] [39] [40] [41] [42] showed a 100% cure rate. Resection was 100% effective in treated animals with untransduced tumors and in animals which received sub-optimal AV.TK treatment. 
Prevention of intracranial tumor formation by subcutaneous AV.TK-transduced tumor cell vaccinations
We examined if any of these manipulations of 9L cells/tumors more effectively induced a vaccination effect (eg surgery or irradiation versus HSVtk/GCVmediated cell death, retroviral versus adenoviral gene delivery, or in vivo GCV treatment versus ex vivo GCV treatment of tumor cells). Animals treated as described above were challenged with an intracranial inoculation of 4 × 10 4 9L cells (4 × tumor formation dose for 100%, TFD 100 ) and followed for survival (Figure 1 ). Animals bearing subcutaneous 9L/STK and given GCV beginning 7 days after tumor implantation (group 3) showed significant survival rate upon subsequent intracranial challenge with 4 × TFD 100 9L cells. By contrast, animals initially receiving 9L/STK/GCV cells that had been exposed to a lethal dose of GCV in vitro and injected before cell death (group 4) did not show the same effect (log-rank test, P Ͻ 0.05). This suggests that lysis of tumor cells exposed to GCV in vivo is more potent in priming immune response than lysis of tumor cells injected after a lethal ex vivo exposure to GCV. When adenovirus was used for transduction, intratumoral AV.TK treatment induced the vaccination response better than ex vivo transduction with AV.TK. When established subcutaneous 9L tumors were treated by in situ injection of AV.TK, a significant protective effect was seen (n = 8/12; group Gene Therapy groups and in animals that received AV.TK and PBS. By contrast, animals that received AV.TK and GCV had an 18% survival rate (4/22) after more than 100 days (logrank test, P Ͻ 0.05) and were apparently cured, surviving beyond 360 days (data not shown). All animals that did not survive had intracranial tumors.
Characterization of cytotoxic T-lymphocytes (CTL)
The results of assays for CTL-mediated target cell lysis by splenocytes prepared from vaccinated animals is shown in Figure 4 demonstrating detected by FACS only in animals immunized with AV.TK/GCV treatment ( Figure 5 ).
Upregulation of MHC class I expression by HSV-tk/GCV treatment
A possible mechanism contributing to tumor-specific CTL induction could be the upregulation of MHC class I expression assisting presentation of tumor-specific epitopes. The expression of MHC class I antigens on 9L cells expressing HSVtk was examined by FACS using an antibody specific for RT1A, the rat class I MHC antigen. Increased cell surface expression of MHC class I antigens was detected. Interestingly, the increased levels of MHC class I molecules were detected only after GCV treatment (Figure 6 ), demonstrating that the onset of GCVmediated toxicity is associated with the induction of MHC class I expression rather than HSVtk expression alone.
Figure 6 MHC class I upregulation mediated by GCV addition to HSVtk expressing tumor cells. MHC class I upregulation was estimated with 9L/STK or 9L cells cultured in a medium with or without 50 m GCV for 24 h. Expression of MHC class I antigens was examined by FACS analysis using an antibody specific for rat RT1A. Dead cells and cell debris were excluded by propidium iodide staining. (a) 9L cells plus antibody R4-22 (isotype standard)-filled curve, 9L cells with GCV plus R4-22-open curve; (b) 9L cells plus antibody B5 (anti-rat MHC Class I)-filled curve, 9L cells with GCV plus B5-open curve; (c) 9L/STK plus R4-22-filled curve, 9L/STK with GCV plus R4-22-open curve; (d) 9L/STK plus B5-filled curve, 9L/STK with GCV plus B5-open curve.
Discussion
In this study we show that in vivo AV.TK/GCV-mediated tumor lysis of subcutaneous tumors functions effectively as a vaccine which enhances systemic antitumor immunity. The AV.TK/GCV treatment of established tumors increased the antitumor immune response, including intracranial protection, but antitumor immunity was undetectable in animals treated with surgical removal of primary tumor or irradiated tumor cell vaccines. Of critical importance, the immunologic benefits of AV.TK/GCV therapy are not dependent upon complete tumor ablation in this model. In this model, surgical resection of untreated tumors did not result in the development of effective antitumor immunity. However, surgical resection of partially regressed AV.TK/GCV-treated tumors showed that AV.TK/GCV could augment the development of concomitant immunity to a tumor that does not ordinarily induce such a response. The immune response generated can be sufficient to protect the animal from a distant tumor, even if that tumor is located in the CNS. These observations suggest that the use of local AV.TK/GCV treatment should be studied in the clinical setting as a potential adjuvant when combined with traditional surgical debulking of tumors that might have already subclinically seeded to distant sites. The augmented immunity may be the result of several contributing factors. In our study, we have found evidence of CTL-mediated killing as a mechanism by which a 'distant bystander' effect can act upon pre-existing tumors at distant sites. The CD8 alpha/beta is a more efficient coreceptor than CD8 alpha/alpha, because it more avidly streng-thens TCR-ligand binding. 31, 32 Although rat peripheral T cells express CD8 alpha/beta heterodimers, T cells infiltrating tumor tissue may have different population of cells. The gamma/delta T lymphocytes infiltrating human lung cancer express the CD8 alpha/alpha homodimer and the cells can be selectively expanded in cancer and accumulated. 33 In our experiment, we observed accumulation of cells expressing beta chain in the tumor of the long-term survivor that was successfully immunized by the AdTK/GCV treatment, while expression of the CD8 beta chain may be below the level of detection in the unvaccinated control.
In experimental brain tumor models using retrovirally transduced 9L cells, HSVtk mediated killing of tumor cells results in long-term tumor regression. 34 The data in those reports suggest that systemic immunity is induced in this system, but immunity against an intracranial tumor induced by adenovirus mediated in situ subcutaneous tumor lysis as the tumor vaccine has not yet been previously observed. Using an adenoviral vector system, this study shows that the AV.TK/GCV treatment for subcutaneous tumors can not only accomplish the induction of long-lasting tumor-specific immunity, but can also induce biologically significant responses against preexisting intracranial tumors. In this study, lethally irradiated 9L cells do not elicit an immune response, suggesting that dying 9L cells are not highly immunogenic per se in the context of protective vaccination. The absence of a protective vaccination response after surgical removal of unmodified 9L tumors confirms that live 9L gliosarcoma cells possess minimal inherent immunogenicity.
Our results indicate that the process of suicide gene/prodrug killing itself plays an important role in the development of long-lasting antitumor immunity. Our results in vitro suggest a correlation between HSVtk/GCV treatment and upregulation of MHC class I expression in 9L cells. Although there is no determination of MHC restriction, some unknown antigen that is MHC class Idependent might be responsible. Other studies have demonstrated that 9L cells express moderate levels of class I MHC antigen and the expression can be increased with IFN-␥. 35, 36 In our study, MHC class I expression on 9L cells might be below the level of detection until it was upregulated following delivery of the virus. The demonstration of GCV-dependent upregulation of MHC class I expression in HSVtk-expressing cells suggests a mechanism by which the induced protective immunity we have seen may develop. A mechanism that involves upregulated MHC expression would not be inconsistent with reports by others that correlate upregulated heat shock protein gene expression to immunogenicity. 16 The systemic immunity which develops after in vivo AV.TK/GCV treatment may be due, in part, to increased expression of the MHC class I molecule by dying cells and that dying cells may be more immunogenic via increased or more efficient antigen presentation. One potential advantage of an in vivo AV.TK/GCV tumor lysis therapy, as compared with the use of ex vivo tumor vaccines, is the expectation of direct tumor cell killing and antigen release in situ, in the presence of local inflammation associated with adenovirus administration. 29 It has been reported that the cells killed by direct HSVtk/GCV mediated cytotoxicity and its associated bystander effect exhibit characteristics of Gene Therapy apoptosis. 37, 38 Increased tumor-specific epitope presentation may occur under these conditions. It has been shown that the dominant mechanism of CTL priming is through the uptake and presentation of tumor antigens by bone marrow-derived antigen-presenting cells. 39 Since the effect of HSVtk expression on MHC class I was minimal in our study, the cross priming mechanism may be important. Additionally, expression of TNF-alpha, 40 IL-1, and IL-6 41 induced by HSVtk/GCV treatment has been reported. We may be observing the product of improved presentation of tumor-specific antigens in the context of immunologic 'danger' as described by Matzinger. 42 Strategies to maximize antitumor immunity induced by the AV.TK/GCV system may include combination therapies of AV.TK/GCV with potent cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-4 or IL-12. Irradiated tumor cells expressing murine GM-CSF stimulated potent, long-lasting, and specific antitumor immunity. 43 The feasibility of preparing a glioma vaccine through retrovirus-mediated GM-CSF transduction of clinical glioma to potentiate antitumor immunity has been suggested. 44 Another group has reported that vaccination with 9L glioma expressing IL-4 and HSVtk genes induced a specific, protective, immune response against rechallenge with parental 9L tumors. 19 Others report that therapies for cancer in mice using adenoviral or retroviral vectors containing IL-12 are highly effective with no significant toxicity. 45, 46 This cytokine induction could stimulate inflammatory injury within the tumor or function to recruit additional effector cells to the site, although increased cytokine expression alone does not appear to have major antitumor or vaccinating effects in this model, and indiscriminate cytokine expression may be counterproductive. 47 Local release of potent cytokines and effective antigen presentation by dying cells, presumably by upregulation of MHC class I expression, might induce systemic antitumor immunity more frequently or in greater magnitude than we have observed in this study.
Materials and methods
Cell lines
The rat glioma cell lines 9L, 48, 49 C6, F98, and a human embryonic kidney cell line 293 50 were cultured in Dulbecco's modified Eagle's media (DMEM; Life Technologies, Gaithersburg, MD, USA) with 10% fetal bovine serum (FBS, Life Technologies), 100 units/ml penicillin, 100 g/ml streptomycin, and 2 mm glutamine at 37°C with 10% CO 2 .
Retrovirus vector and transduction of glioma cells
Rat 9L gliosarcoma cells were transduced in vitro using supernatant from a confluent culture of PA317.STK retroviral producer cells 51 to generate 9L/STK as described previously. 52 Transduced cells were selected in G418 (1.0 mg/ml, Life Technologies) containing growth medium for 14 days and independent colonies were isolated and expanded.
Adenovirus vector construction and transduction of glioma cells
The adenoviral shuttle plasmid pAVS6 has been reported. 53 The pAVS6TK plasmid vector contains the adenoviral left inverted terminal repeat (ITR) and packaging signal, the Rous sarcoma virus (RSV) promoter, the HSVtk gene, the SV40 polyadenylation signal, and a 2.9 kb segment of adenovirus serotype 5 corresponding to nucleotides 3329-6248. The adenoviral vector, AV.TK, was obtained by homologous recombination with the larger ClaI fragment of dl 327 on 293 cells and amplified to a titer of 1.2 × 10 11 p.f.u./ml using standard technique. 54 For ex vivo transduction of 9L cell lines with the AV.TK, the adenovirus vector was added at a multiplicity of infection (MOI) of 100 for 4 h. The medium was exchanged and cells were incubated for an additional 12 h. Tumor volumes were calculated according to the formula V = A × B 2 (V = tumor volume, A = largest diameter, B = smallest diameter). 55 Those animals failing initial therapies which were selected for rechallenge experiments had residual subcutaneous tumors surgically removed before rechallenge. All animal studies were performed in accordance with the National Institutes of Health Guidelines for the Care of Laboratory Animals and were approved by the NHGRI Animal Care and Use Committee.
Adenoviral HSVtk/GCV mediated elimination of subcutaneous 9L tumors
Intracranial challenge experiments
Forty thousand 9L cells were implanted in the right caudate nucleus as previously described, 5 28 days after immunization. Rats were anesthesized, placed in a stereotactic head frame (David Kopf, Los Angeles, CA, USA), and cells were placed 5 mm below the dura via a burrhole, 3 mm to the right, and 1 mm anterior to point bregma. Survival was analyzed using the log-rank test.
An additional group of animals was subcutaneously inoculated with 9L tumors and then subjected to intracranial inoculation of 9L cells 4 days later. Subcutaneous tumors were treated with AV.TK/PBS (n = 6) or AV.TK/GCV (n = 22) 7 days after the subcutaneous tumor inoculation, as described above (average tumor volume 50 mm 3 ). In one subgroup of control animals which did not receive AV.TK (n = 12) or GCV, the subcutaneous tumors were surgically removed on day 14 to permit long-term observation and evaluation of the intracranial tumor. Statistical comparisons of survival data for this study were performed by log-rank analysis.
Cytotoxic T cell assay
Splenocytes were harvested from freshly killed animals and placed in culture media containing 10% rat serum or rat culture supplement T-STIM (Collaborative Biomedical Products, Bedford, MA, USA) for 5 days in the presence of 5 × 10 5 irradiated 9L cells (10 000 rads). These prestimulated effector cells were coincubated with Cr 51 -labeled target cells for 4 h at 37°C in different effector to target cell ratios. Control parental 9L cells, syngeneic F-98 glioma cells, and allogeneic C6 glioma cells were used as targets for the CTL assay. After incubation, 100 l of the supernatant was assayed in a gamma counter. The percentage of specific cytolysis was calculated as (experimental release − spontaneous release)/(maximum release − spontaneous release) × 100. The total radioactivity present in target cells was analyzed by lysing the cells with 10% SDS. In vitro CTL-mediated lysis by splenocytes harvested from AV.TK/GCV treated animals was measured in the presence and absence of anti-CD8␤ antibody 341 (Pharmingen, San Diego, CA, USA) or isotype control 107.3 (Pharmingen).
Tumor infiltrating lymphocytes (TILs) harvested from animals used in the above CTL analysis were examined by flow cytometry. Tumor infiltrating lymphocytes (TILs) were isolated with a triple enzyme solution containing 0.1% collagenase type IV, 0.002% deoxyribonuclease type IV, and 0.01% hyaluronidase typeV. 56 TILs obtained on day 5 of co-culture with irradiated 9L cells and rat culture supplement T-STIM were analyzed by flow cytometry (FACscan; Becton-Dickinson, San Jose, CA, USA) for expression of CD8␣ and CD8␤. OX-8 (Pharmingen; 1:1000 dilution) identified CD8␣-equivalent cells, and 341 (Pharmingen; 1:1000 dilution) identified CD8␤-equivalent cells. Negative controls were cells stained with mouse IgG isotype standard 107.3 (Pharmingen; 1:1000 dilution).
MHC class I upregulation by HSVtk/GCV treatment MHC class I upregulation was estimated with 9L/STK or 9L cells cultured in a medium with or without 50 m GCV for 24 h. Live cells were purified by gradient centrifugation with Lympholyte-Rat (Accurate, Westbury, NY, USA). Expression of MHC class I antigens on cells was examined by immunofluorescence using the antibody B5 (Pharmingen; 1:1000 dilution) which is specific for rat RT1A (MHC class I). The negative controls were cells stained with rat IgM isotype standard R4-22 (Pharmingen; 1:1000 dilution). Dead cells and cell debris were excluded from flow cytometric analysis after propidium iodide staining (Boehringer Mannheim, Indianapolis, IN, USA) for cellular DNA.
